Abstract:CONTEXT: Recent debates and events have brought into question the effectiveness of existing regulatory frameworks for medical devices in the United States and Europe to ensure their performance, safety, and quality. This article provides a comparative analysis of medical device regulation in the two jurisdictions, explores current reforms to improve the existing systems, and discusses additional actions that should be considered to fully meet this aim. Medical device regulation must be improved to safeguard public health and ensure that high-quality and effective technologies reach patients.METHODS: We explored and analyzed medical device regulatory systems in the United States and Europe in accordance with the available gray and peer-reviewed literature and legislative documents.FINDINGS: The two regulatory systems differ in their mandate and orientation, organization, pre- and postmarket evidence requirements, and transparency of process. Despite these differences, both jurisdictions face similar challenges for ensuring that only safe and effective devices reach the market, monitoring real-world use, and exchanging pertinent information on devices with key users such as clinicians and patients. To address these issues, reforms have recently been introduced or debated in the United States and Europe that are principally focused on strengthening regulatory processes, enhancing postmarket regulation through more robust surveillance systems, and improving the traceability and monitoring of devices. Some changes in premarket requirements for devices are being considered.CONCLUSIONS: Although the current reforms address some of the outstanding challenges in device regulation, additional steps are needed to improve existing policy. We examine a number of actions to be considered, such as requiring high-quality evidence of benefit for medium- and high-risk devices; moving toward greater centralization and coordination of regulatory approval in Europe; creating links between device identifier systems and existing data collection tools, such as electronic health records; and fostering increased and more effective use of registries to ensure safe postmarket use of new and existing devices.

Orphan and paediatric medical devices in Europe: recommendations to support their availability for on-label and off-label clinical indications

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

PP31 Medical Device Regulation: What Is New?

An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations

Barriers to and facilitators of paediatric medical device innovation: a scoping review protocol

Evaluation of orphan maintained biological medicinal products in the European Union between 2018 to 2023: a regulatory perspective

A review of the literature on the new European Medical Device Regulations requirements for increased clinical evaluation

PRE-MARKET CLINICAL EVALUATIONS OF INNOVATIVE HIGH-RISK MEDICAL DEVICES IN EUROPE

Exploring Impediments Imposed by the Medical Device Regulation EU 2017/745 on Software as a Medical Device

Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective

Improving Medical Device Regulation: The United States and Europe in Perspective

The Challenges for Manufacturers of the Increased Clinical Evaluation in the European Medical Device Regulations: A Quantitative Study

Regulation of orthopaedic devices: Future implications for research and innovation

Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review

Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight

Neither protective nor harmonized: the crossborder regulation of medical devices in the EU

Trends in orphan medicinal products approvals in the European Union between 2010–2022

New medical device regulations: the regulator’s view

Challenges faced by manufacturers with clinical evaluation under the new European Medical Device Regulations

Recent regulatory developments in EU Medical Device Regulation and their impact on biomaterials translation

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union